Sjogren's syndrome is a disease where the body's immune system attacks its own cells, causing dryness in the mouth and eyes. This study is for people who have already been part of a previous study called NEPTUNUS. It aims to see how safe and effective a drug called ianalumab is over a long time. Ianalumab is a medicine given by a shot under the skin, using a pre-filled syringe. The study will last for up to 5 years, with 3 years of treatment and up to 2 years of follow-up. There are about 600 participants expected, and visits will be mostly monthly.

• The study lasts up to 5 years with regular visits.
• Participants receive a medicine called ianalumab, either every month or every 3 months.
• There are no new participants; only those from prior studies can join.

Before joining, participants must have completed a previous study and should not plan to take certain other medicines or vaccines. Pregnant or nursing women cannot join. Women who could become pregnant must use effective birth control. Safety is closely monitored, and study members can learn to self-inject at home after training. This study helps researchers understand if ianalumab is safe and works well for people with Sjogren's syndrome over a long time.